Company Overview
DBV Technologies S.A. operates as a clinical-stage biopharmaceutical company dedicated to the research and development of epicutaneous immunotherapy products specifically within the French market. The company focuses its efforts on creating treatments that utilize this specific therapeutic approach, with its primary product pipeline consisting of Viaskin Peanut, which has successfully completed Phase 3 clinical trials for the treatment of peanut allergy. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, a classification that signifies an organization reliant on scientific innovation and clinical research to generate value. The company currently maintains a market capitalization of $1.09B and employs a workforce of 117 individuals to support its operations. These valuation and revenue figures indicate that the company is a mid-cap entity within its sector, reflecting a significant investment by the market despite the lack of current profitability, while the employee count suggests a lean organizational structure typical of early-stage biotech firms.
Financial Health
The company reported annual revenue of $5.50M for the trailing twelve months, yet this revenue generated a net income of $-125,133,000, revealing a severe cost structure where expenses vastly exceed income. EBITDA data is not available for this reporting period, which further obscures the cash operating performance in the absence of net income. The free cash flow stands at $-51,063,248, indicating that the company is burning through cash reserves to fund its research and development activities rather than generating surplus liquidity. Three distinct margin metrics highlight the financial state: a gross margin of 100.0%, an operating margin of -1235.7%, and a profit margin of 0.0%. The 100.0% gross margin suggests that the cost of goods sold is negligible relative to revenue, likely due to the nature of intellectual property licensing or low manufacturing costs, while the negative operating and profit margins confirm that overhead and R&D expenses are consuming all revenue and more. The company holds $69.84M in cash against $7.69M in debt, resulting in a debt-to-equity ratio of 14.55. Despite the high debt-to-equity figure, the substantial cash balance provides a conservative cushion against short-term obligations, though the leverage ratio technically classifies the balance sheet as highly leveraged relative to equity. The current ratio is 1.80, which indicates a healthy level of short-term liquidity, ensuring the company can meet its current liabilities with its current assets. Return on Equity is -234.1% and Return on Assets is -77.3%, metrics that reveal management is currently destroying value per unit of equity and assets rather than generating returns.
Valuation Assessment
Valuation multiples for DBV Technologies S.A. present a complex picture, with a P/E Ratio (TTM) of N/A due to negative earnings and a Forward P/E of -38.33. The negative forward P/E implies that the market expects earnings to remain negative or for the company to continue incurring losses in the near future, preventing the establishment of a traditional earnings-based valuation multiple. The price-to-book ratio is 50.65, which indicates a significant market premium over the company's book value, suggesting investors are pricing in substantial future growth potential or successful clinical outcomes despite current financials. Alternative valuation metrics such as the price-to-sales ratio of 197.73 and an EV/EBITDA of N/A further emphasize that traditional profitability measures are insufficient for valuing this asset, forcing reliance on revenue-based multiples. The stock has traded within a 52-week range between a high of $26.18 and a low of $3.91. Without a specific current share price provided in the source facts, the exact percentage distance from the 52-week high cannot be calculated; however, the wide range of $22.27 demonstrates high historical volatility. The beta value is -0.21, a negative figure that implies the stock price tends to move in the opposite direction of the broader market, exhibiting a volatility profile that is inversely correlated with general market trends.
Growth & Income
The company demonstrated robust expansion with a revenue growth (YoY) of 158.8%, while earnings growth (YoY) is N/A due to the lack of prior year comparable positive earnings. Because earnings are currently negative, the standard comparison of earnings growth versus revenue growth is not applicable, but the massive revenue increase suggests rapid adoption or successful market penetration for its immunotherapy products. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution is typical for clinical-stage biopharmaceutical companies, as the 0.0% payout ratio is mathematically sustainable only because there are no earnings to distribute, confirming that all available resources are being reinvested into the business rather than returned to shareholders. Since the company is not a dividend payer, the income profile is entirely reliant on capital appreciation rather than yield. The overall growth and income profile is characterized by aggressive top-line expansion funded by cash reserves, with no current income generation from dividends or net income to support shareholder returns.